Skip to main content
Windlas Biotech Limited logo

Windlas Biotech Limited — Investor Relations & Filings

Ticker · WINDLAS ISIN · INE0H5O01029 LEI · 3358008HGGLMCSC4GP83 BSE.NS Manufacturing
Open in API
Filings indexed 435 across all filing types
Latest filing 2024-09-12 Regulatory Filings
Country IN India
Listing BSE.NS WINDLAS

About Windlas Biotech Limited

https://www.windlasbiotech.com

Windlas Biotech Limited is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from formulation development to commercial-scale production. The company specializes in manufacturing solid and liquid oral dosage forms, including tablets, capsules, sachets, and liquid orals. Its operations encompass three primary business verticals: CDMO services for domestic and multinational firms, trade generics, and over-the-counter (OTC) brands. Windlas maintains advanced research and development facilities focused on process optimization and complex generic formulations. The product portfolio covers diverse therapeutic areas such as gastrointestinal, cardiovascular, anti-diabetic, and respiratory health. The company emphasizes scalable manufacturing solutions and adherence to global quality standards to support the product lifecycles of its pharmaceutical partners.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing about the schedule of analyst and institutional investor meetings. It explicitly states that the discussions will be based on publicly available information and no unpublished price sensitive information will be shared. The document references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which pertains to disclosure of material events or information. The document is short (2040 characters) and serves as an announcement of upcoming investor meetings rather than a detailed report or transcript. It does not contain financial data, earnings, or detailed presentations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2024-09-12 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing them about the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and explicitly states that the discussions will be based on publicly available information with no unpublished price sensitive information to be discussed. The document is short (2019 characters) and serves as an intimation or announcement rather than a detailed report or transcript. It does not contain financial data, earnings results, or detailed presentations. This fits the category of a Regulatory Filing (RNS) as it is a compliance-related announcement that does not fit into more specific categories like Investor Presentation or Call Transcript.
2024-09-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing about the schedule of analyst and institutional investor meetings. It explicitly states that the discussions will be based on publicly available information and no unpublished price sensitive information will be shared. The letter is submitted pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which relates to disclosure of events or information. The document does not contain any financial data, report, or detailed presentation but is an announcement of an upcoming investor interaction event. Therefore, it fits best under the category of Investor Presentation (IP) as it relates to investor/analyst meetings and presentations, even though the actual presentation is not included, the notice is about such an event. However, since the document is only an intimation of the schedule of meetings and does not contain the presentation itself, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a regulatory disclosure about an event rather than the event content or report itself. The document length is short (2086 characters), and it is an announcement rather than a report or transcript. Hence, the best classification is Regulatory Filings (RNS).
2024-09-10 English
Corrigendum
Regulatory Filings
2024-09-09 English
Copy of Newspaper Publication
Regulatory Filings
2024-08-30 English
Updates
AGM Information Classification · 100% confidence The document is a detailed notice of the 23rd Annual General Meeting (AGM) of Windlas Biotech Limited scheduled for September 24, 2024. It includes information about the meeting agenda, such as adoption of audited financial statements for the fiscal year ended March 31, 2024, declaration of dividend, appointment of director, and ratification of auditor remuneration. It also provides procedural details about e-voting, cut-off dates, and regulatory compliance references. The document is not the annual report itself but the official notice calling the AGM and providing related information to shareholders. Therefore, it fits the category of AGM Information (AGM-R). The document length is substantial and contains the full notice, not just a brief announcement or link to a report, confirming it is the AGM notice document itself.
2024-08-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.